Hoth Therapeutics’ HT-KIT Shows Strong Preclinical Anti-Tumor Results
September 2, 2025
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has shared encouraging results from several preclinical studies on its precision antisense drug candidate HT-KIT. The findings show